COMMUNICATIONS
TO THE EDITOR Epoxyquinol B, a Fungal Metabolite with a Potent Antiangiogenic Activity Sir:
Angiogenesis, the formation of new capillaries from preexisting vessels, is a prerequisite for many physiological processes, including embryonic development, wound healing, and female reproductive functions. Moreover, a number of pathological conditions such as cancer, rheumatoid arthritis, and other chronic inflammatory diseases are characterized by extensive angiogenesis. [1] [2] [3] [4] [5] Recent studies have revealed that vascular endothelial growth factor (VEGF) plays a pivotal role in pathological situations that involve neovascularization as well as enhanced vascular permeability. Additionally, VEGF has been shown to strongly induce cell migration, proliferation, and tube formation with a unique specificity for endothelial cells.6,7) Consequently the concept that progression of various diseases may be halted by inhibiting endothelial cell functions has raised considerable interest.8)
In a previous paper, we have already reported a novel fungal metabolite, epoxyquinol A (1), as an angiogenesis inhibitor.9) The continuous bioassy-guided purification led to a more potent angiogenesis inhibitor, epoxyquinol B (2), a unique diastereomer of 1 in respect to the structure, biosynthesis, and biological properties. In this communication, the isolation, structure, and biological activities of epoxyquinol B (2) are reported.
The producing fungal strain was cultured in a 30-liter jar fermenter containing 18 liters of fermentation medium (glucose 1%, soluble starch 2%, soybean meal 1.5%, malt extract 0.5%, vegetable extract 10%, potato dextrose 2.5%, 350rpm and an aeration rate of 10 liters/minute for 96 hours. The active principle was extracted with ethyl acetate from culture filtrate adjusted to pH 7.0. The solvent layer was dried over Na2SO4 and concentrated in vacuo to give an oily residue. This material was subjected to silica gel column chromatography with 0-50% methanol in chloroform stepwise. Epoxyquinol B (2) was eluted with 10% methanol in chloroform, and was purified on preparative HPLC using a reverse phase column (PEGASIL with a gradient solvent system of CH3CN-water (from 20:80 to 50:50). Final purification by preparative silica gel thin-layer chromatography (CHCl3-MeOH=10:1) gave 50mg of epoxyquinol B (2). Epoxyquinol B (2) The 1H and 13C NMR spectral analysis including 2D NMR techniques (PFG-DQFCOSY, PFG-HMQC, and PFG-HMBC) revealed that the plain structure of 2 was the same as that of 1. Relative stereochemistry between hydroxy and epoxy groups of both epoxyquinol moieties of 2 was determined to be trans configuration from the small coupling constant values of 3JH-3,H-4 and 3JH-13,H-14. Significant NOEs observed between H-8 and H-19 as well as H-9 and H-18 confirmed the sequential stereochemistry at C-9, C-8, C-18, and C-19. Moreover, the isolated methine proton H-1 displayed significant NOEs with H-14, H-15, and 3-OH, thereby establishing the stereochemistry at C-1, C-17, C-13, and C-3. Thus, the relative stereochemistry of 2 was unambiguously determined as shown in Figure 1 . As the asymmetric total synthesis of 1 and 2 has been completed,10) this stereochemistry including their absolute stereochemistry is confirmed.
Epoxyquinol B (2) has the opposite configurations at C-17, C-18, and C-19 in comparison with those of 1.
Although several biosynthetic pathways for the production of 2 could be considered, one possible path is shown in 
